Literature DB >> 19725849

Valvular heart disease in osteogenesis imperfecta: presentation of a case and review of the literature.

Raphael E Bonita1, Ira S Cohen, Barbara A Berko.   

Abstract

Osteogenesis imperfecta (OI) is a rare inheritable disorder of connective tissue. While musculoskeletal abnormalities are well known, cardiovascular involvement is rare. Aortic root dilation is the most common cardiovascular manifestation. OI preferentially affects the left-sided heart valves, for unclear reasons, leading to aortic and mitral regurgitation. Valve replacement surgery carries a unique set of issues in this population, and fewer than 40 cases have been reported. We report a case of chronic severe aortic regurgitation in a patient with OI complicated by the development of a flail aortic valve leaflet and presenting with a transient ischemic attack. The patient subsequently underwent successful combined bioprosthetic aortic valve replacement and coronary artery bypass grafting. We review the literature on valvular disease and other cardiovascular manifestations in OI and the related surgical considerations relevant to this patient population.

Entities:  

Mesh:

Year:  2009        PMID: 19725849     DOI: 10.1111/j.1540-8175.2009.00973.x

Source DB:  PubMed          Journal:  Echocardiography        ISSN: 0742-2822            Impact factor:   1.724


  12 in total

1.  Surgical technique of double valve replacement in a patient with osteogenesis imperfecta.

Authors:  Mizuki Sumi; Tsuneo Ariyoshi; Seiji Matsukuma; Shun Nakaji; Koji Hashizume; Naoe Kinoshita; Kiyoyuki Eishi
Journal:  Gen Thorac Cardiovasc Surg       Date:  2014-06-11

Review 2.  New perspectives on osteogenesis imperfecta.

Authors:  Antonella Forlino; Wayne A Cabral; Aileen M Barnes; Joan C Marini
Journal:  Nat Rev Endocrinol       Date:  2011-06-14       Impact factor: 43.330

3.  Differential activation of valvulogenic, chondrogenic, and osteogenic pathways in mouse models of myxomatous and calcific aortic valve disease.

Authors:  Jonathan D Cheek; Elaine E Wirrig; Christina M Alfieri; Jeanne F James; Katherine E Yutzey
Journal:  J Mol Cell Cardiol       Date:  2012-01-10       Impact factor: 5.000

Review 4.  Advances in the Classification and Treatment of Osteogenesis Imperfecta.

Authors:  Inas H Thomas; Linda A DiMeglio
Journal:  Curr Osteoporos Rep       Date:  2016-02       Impact factor: 5.096

Review 5.  Transcriptional regulation of heart valve development and disease.

Authors:  Elaine E Wirrig; Katherine E Yutzey
Journal:  Cardiovasc Pathol       Date:  2010-08-11       Impact factor: 2.185

6.  Anesthetic and Surgical Considerations in Osteogenesis Imperfecta: A Case Report of Mandible Fracture Management.

Authors:  Taleaa Masroor; Ava Ganson Chappell; Farooq Shahzad
Journal:  Eplasty       Date:  2022-05-05

7.  Functional and structural studies of tolloid-like 1 mutants associated with atrial-septal defect 6.

Authors:  Lukasz Sieron; Marta Lesiak; Izabela Schisler; Zofia Drzazga; Andrzej Fertala; Aleksander L Sieron
Journal:  Biosci Rep       Date:  2019-01-08       Impact factor: 3.840

8.  On the shape and structure of the murine pulmonary heart valve.

Authors:  Yifei Liu; Xinzeng Feng; Hao Liu; David W McComb; Christopher K Breuer; Michael S Sacks
Journal:  Sci Rep       Date:  2021-07-07       Impact factor: 4.379

9.  Cardiopulmonary dysfunction in the Osteogenesis imperfecta mouse model Aga2 and human patients are caused by bone-independent mechanisms.

Authors:  Frank Thiele; Christian M Cohrs; Armando Flor; Thomas S Lisse; Gerhard K H Przemeck; Marion Horsch; Anja Schrewe; Valerie Gailus-Durner; Boris Ivandic; Hugo A Katus; Wolfgang Wurst; Catherine Reisenberg; Hollis Chaney; Helmut Fuchs; Wolfgang Hans; Johannes Beckers; Joan C Marini; Martin Hrabé de Angelis
Journal:  Hum Mol Genet       Date:  2012-05-15       Impact factor: 6.150

10.  Cardiovascular involvement in children with osteogenesis imperfecta.

Authors:  Hamdollah Karamifar; Homa Ilkhanipoor; Gholamhossein Ajami; Zohreh Karamizadeh; Gholamhossein Amirhakimi; Ali-Mohammad Shakiba
Journal:  Iran J Pediatr       Date:  2013-10       Impact factor: 0.364

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.